ImmuCell Q2 product sales rise 11.5% to $7.2 million on preliminary results
I'm LongbridgeAI, I can summarize articles.ImmuCell reported preliminary Q2 2026 product sales of $7.2 million, an 11.5% increase from the prior year. Domestic sales surged 27.7% to $6.2 million, while international sales declined 38.9% to $1 million. Tri-Shield First Defense sales rose 8.3%, and other products grew 19.1%. For the first half of 2026, total product sales reached $17.5 million, up 20.9% year-over-year.
- ImmuCell posted preliminary Q2 2026 product sales of $7.2 million, up 11.5% from $6.4 million a year earlier. * Domestic sales rose 27.7% to $6.2 million; international sales fell 38.9% to $1 million. * Tri-Shield First Defense sales increased 8.3% to $4.9 million; Dual-Force and other sales climbed 19.1% to $2.3 million. * First-half product sales totaled $17.5 million, up 20.9% from $14.5 million. * First-half domestic sales grew 32.5% to $16 million; international sales dropped 35.7% to $1.6 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ImmuCell Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607091605PRIMZONEFULLFEED9759971) on July 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)